- Home
- UONEK vs GLTO Comparison
UONEK vs GLTO Comparison
Compare UONEK & GLTO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- UONEK
- GLTO
- Stock Information
- Founded
- UONEK 1980
- GLTO 2011
- Country
- UONEK United States
- GLTO Denmark
- Employees
- UONEK N/A
- GLTO N/A
- Industry
- UONEK Broadcasting
- GLTO Biotechnology: Pharmaceutical Preparations
- Sector
- UONEK Consumer Discretionary
- GLTO Health Care
- Exchange
- UONEK Nasdaq
- GLTO Nasdaq
- Market Cap
- UONEK 22.8M
- GLTO 23.7M
- IPO Year
- UONEK N/A
- GLTO 2020
- Fundamental
- Price
- UONEK $0.49
- GLTO $26.31
- Analyst Decision
- UONEK
- GLTO
- Analyst Count
- UONEK 0
- GLTO 0
- Target Price
- UONEK N/A
- GLTO N/A
- AVG Volume (30 Days)
- UONEK 107.2K
- GLTO 3.1M
- Earning Date
- UONEK 11-04-2025
- GLTO 11-06-2025
- Dividend Yield
- UONEK N/A
- GLTO N/A
- EPS Growth
- UONEK N/A
- GLTO N/A
- EPS
- UONEK N/A
- GLTO N/A
- Revenue
- UONEK $393,670,000.00
- GLTO N/A
- Revenue This Year
- UONEK N/A
- GLTO N/A
- Revenue Next Year
- UONEK N/A
- GLTO N/A
- P/E Ratio
- UONEK N/A
- GLTO N/A
- Revenue Growth
- UONEK N/A
- GLTO N/A
- 52 Week Low
- UONEK $0.44
- GLTO $2.01
- 52 Week High
- UONEK $1.40
- GLTO $33.60
- Technical
- Relative Strength Index (RSI)
- UONEK 35.31
- GLTO 77.29
- Support Level
- UONEK $0.46
- GLTO $15.00
- Resistance Level
- UONEK $0.52
- GLTO $29.03
- Average True Range (ATR)
- UONEK 0.05
- GLTO 3.60
- MACD
- UONEK -0.00
- GLTO 2.19
- Stochastic Oscillator
- UONEK 15.08
- GLTO 73.89
About UONEK Urban One Inc. Class D
Urban One Inc is an urban oriented, multi-media company. Its business is radio broadcasting franchise that is the radio broadcasting operation that targets African-American and urban listeners. It operates through the following segments: Radio Broadcasting, Reach Media, Digital, and Cable Television. The Radio Broadcasting segment includes all the broadcasting related operations. The Reach Media segment consists of the Tom Joyner Morning Show and its related activities. The Digital segment focuses on its online business, including the operations of Interactive One. The Cable Television segment deals with TV One's operations.
About GLTO Galecto Inc.
Galecto Inc is a clinical-stage biotechnology company developing therapeutics designed to target the biological processes that lie at the heart of cancer and liver diseases. Its initial focus is on the development of small-molecule inhibitors of galectin-3 and lysyl oxidase-like 2, or LOXL2. Its product candidate GB0139 is for the treatment of severe fibrotic lung diseases such as idiopathic pulmonary fibrosis, or IPF, a life-threatening progressive fibrotic disease of the lung. Its product GB1211, a selective oral galectin-3 inhibitor for the treatment of fibrosis related to non-alcoholic steatohepatitis, or NASH, and GB2064, a selective oral inhibitor of LOXL2 that it initially plans to develop for the treatment of myelofibrosis.